For patients

Is IndiTreat right for you as a cancer patient?

IndiTreat® could help your doctor choose a better cancer treatment for you

There are many forms of cancer, and an individual patient’s cancer might respond to certain drugs but not to others. For some conditions, IndiTreat® could help your doctor choose the right treatment for you, and avoid the ones that are less likely to work.

IndiTreat has received CE validation for testing drugs on colorectal cancer. This means that cancer clinics in the EU and the UK can order the test for this disease.

Medical treatment of solid cancers are usually based on guidelines from established, international cancer societies. Treatment begins with a first line therapy. If you are resistant to the drug or experience intolerable side effects, treatment is modified to a second line therapy involving a different drug or drug combination. If second line therapy is ineffective, there is rarely more help to be gained from guidelines and subsequent treatment may be experimental or based on your doctor’s experience.

In the current situation, IndiTreat® testing might be considered by your doctor after an ineffective second line therapy and if a tumor biopsy (removing a small sample of the. tumor) is possible. You can ask your doctor if it is possible to get an IndiTreat® test earlier. Even in guidelines for first line therapy, there are choices that your oncologist makes, where IndiTreat can help make his choice of treatment.

To ask your doctor if IndiTreat is appropriate for you, download this document and share it with your doctor or oncologist.

Introducing IndiTreat® from 2cureX

Contact us

Please contact 2cureX for more information

Phone: +45 22115399

Upcoming events

December 7, 2021

CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)

Read more

December 9, 2021

2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)

Read more

January 20, 2022

2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)

Read more

February 24, 2022

Year-End Report 2021

View previous reports

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs